Pacira BioSciences
PCRX
253 hedge funds and large institutions have $1.12B invested in Pacira BioSciences in 2026 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 82 increasing their positions, 84 reducing their positions, and 24 closing their positions.
266% more call options, than puts
Call options by funds: $827K | Put options by funds: $226K
58% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 24
13% more capital invested
Capital invested by funds: $986M → $1.12B (+$130M)
5% more funds holding
Funds holding: 242 → 253 (+11)
3.49% more ownership
Funds ownership: 107.71% → 111.21% (+3.5%)
2% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 84
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$8.47M |
| 2 |
Two Sigma Investments
New York
|
+$4.67M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$4.27M |
| 4 |
Millennium Management
New York
|
+$4.21M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$15M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$6.85M |
| 3 |
Morgan Stanley
New York
|
-$5.86M |
| 4 |
Jane Street
New York
|
-$3.32M |
| 5 |
PFC
Phocas Financial Corp
Alameda,
California
|
-$2.59M |
PCRX Hedge Fund Activity: Q2 2026 in Review
253 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2026, worth a combined $1.12B — up 13% from $986M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PCRX positions and 24 closed out — a net gain of 14 holders — while 82 added to existing stakes and 84 trimmed.
The largest buyer was UBS Group, adding an estimated $8.47M. The largest seller was Citadel Advisors, cutting an estimated $15M.
- 253 institutional investors held Pacira BioSciences (PCRX) as of Q2 2026, up from 242 in Q1 2026.
- Funds reported $1.12B of Pacira BioSciences stock for Q2 2026, up 13% quarter-over-quarter.
- 38 funds opened new Pacira BioSciences positions in Q2 2026 and 24 closed out, a net change of +14 holders.
- The largest Pacira BioSciences buyer in Q2 2026 was UBS Group, an estimated $8.47M added.
- The largest Pacira BioSciences seller in Q2 2026 was Citadel Advisors, an estimated $15M sold.
Based on aggregated 13F filings for Q2 2026.